Background Cognitive impairment is strongly linked with persistent disability in people with mood disorders, but the factors that explain cognitive impairment in this population are unclear.
Introduction
Cognitive impairment is a key determinant of occupational and social outcomes and quality of life in people with mood disorders. 1, 2 Up to 57% of adults with bipolar disorder (BD) and up to one-half of adults with major depression show clinically significant levels of cognitive impairment, even in euthymia. 3, 4 In BD, impairment is typically found on tests of attention, working and episodic memory, processing speed, and executive function, with group differences of medium to large effect size compared with adults without a history of psychiatric illness. 5, 6 The profile of impairment is similar in major depression, but with effect sizes of smaller magnitude. 7 The causal nature of this relationship is unclear, however, because approaches to accounting for confounding influences have been inconsistent in the literature. Moving towards causal explanations requires careful modelling of a range of potential confounding, mediating and moderating factors, acknowledging the complexity of their inter-relationships with mood disorder exposure, cognitive outcome, and each other. The application of novel confounder control techniques in psychiatric epidemiology is not yet widespread. The counterfactual approach, in which causal effects are conceptualized as alternative 'potential outcomes' of an exposure, can be linked with graphical notation in the form of directed acyclic graphs (DAG) to systematically identify causal effects in complex systems. 8, 9 This, in turn, informs rigorous statistical analyses and clarifies the assumptions needed to interpret estimates as causal. In this study, we applied a graphical approach to understand the structure of confounding and mediation with regard to cognitive performance in UK Biobank 10 participants with a history of BD or major depression. We estimated the total effect of BD and major depression on cognitive function, and the magnitude of the effect that was transmitted through potentially modifiable intermediate factors.
Method
Participants UK Biobank recruited adults from the general population across 22 centres in Great Britain between 2006 and 2010. The target age range was 40 to 69 years and no other exclusion criteria were applied. Postal invitation lists were generated from National Health Service (NHS) registers, with a response rate of approximately 6%. Cross-sectional data from the full cohort at baseline (N=502,618) were used. Participants were included in the analysis if they had sufficient data to classify their BD or major depression exposure status (see below) and had data on at least one cognitive outcome measure. The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. All procedures involving human participants were approved by the North West -Haydock NHS Research Ethics Committee (reference 16/NW/0274 and 11/NW/0382). Written informed consent was obtained from all participants.
Mood Disorder Status
Three sources of information were available regarding history of mood disorder: self-reported doctor diagnosis; probable classification based on self-reported lifetime mood disorder symptoms and help-seeking; 11 and linked NHS hospital inpatient and day case records. The definitions used in these sources are provided in the eMethods in the Supplement. To permit consistency across each information source, single manic episode and BD were analysed as one exposure (mania/BD), and the major depression exposure included single episode and recurrent illness.
Participants were classified as exposed if they were positive for mania/BD or major depression in at least one information source. Mania/BD and major depression were then separated hierarchically into two mutually exclusive exposure groups. Participants with a record of both mania/BD and major depression were classified in the mania/BD group only.
The unexposed comparison group comprised participants who had complete self-reported data that did not indicate mania/BD or major depression, and whose hospital records had no primary or secondary diagnosis of mania/BD or major depression. Furthermore, because misclassification is common between mania/BD and schizophrenia spectrum disorders, 12 participants with a self-reported diagnosis or hospital record of schizophrenia (ICD-10 code F20x) were excluded from all exposed and unexposed groups. In summary, the final groups for analysis were: mania/BD (excluding participants with only major depression, and those with schizophrenia); major depression (excluding participants with mania/BD, and those with schizophrenia); and unexposed (complete data indicating no mania/BD or major depression or schizophrenia). Participants who did not meet the above criteria for either the exposed or unexposed groups were not further analysed (e.g. those with incomplete data, preventing inclusion in the unexposed group).
Cognitive Outcome Measures
The cognitive measures analysed were reasoning, reaction time, numeric memory, visuospatial memory and prospective memory, as described in detail elsewhere. 13 All were administered via a touchscreen computer. The psychometric properties of these tests have been reported previously. 14 The data were provided by UK Biobank as raw scores, and for the purposes of the present analysis were standardized within five-year age strata, using all available data in the cohort at baseline. Five-year bands were deemed appropriate in light of the typical rate of age-related change in cognitive performance in middle to older adulthood. 15 To address skew in the raw data distributions, the scores were first transformed into percentiles and then into z-scores (mean = 0 and standard deviation [SD] = 1). The scores for reaction time and visuospatial memory were reflected so that higher scores 6 represent better performance, in line with the other tests. It was not possible to standardize the prospective memory data in this way because responses were dichotomized (correct response at the first attempt or not), and so the raw data were used in the analyses involving this test. 
Mental health and psychotropic medication
In addition to the self-reported and hospital records data regarding psychiatric diagnoses, participants also provided self-reported information at baseline about depressive symptoms in the past two weeks, and current psychotropic medications (dichotomous indicator for any mood stabilizer, antidepressant, antipsychotic, sedative or hypnotic), as detailed in the eMethods in the Supplement. Self-reported information regarding number of episodes of depressed mood or anhedonia was collected at baseline and in a web-based follow-up questionnaire in 2016, and data regarding childhood trauma experiences were also collected in the web-based questionnaire (see eMethods).
Genome-wide polygenic scores
Genome-wide polygenic scores (GPS) were generated for cognitive ability, BD, and major depression, based on summary statistics from previous genome-wide association studies (GWAS). Full details of the genotyping data, GPS methods, and optimum scores used in the present analyses are provided in the eMethods in the Supplement.
Statistical Analyses

Graphical models
The analyses were informed by a graphical model in the form of a DAG, which is used to visually represent qualitative causal assumptions. 16 The structural nature of these assumptions permits the detection of implied patterns of dependency and independency among variables, which can then be tested with data. Structural analysis of the DAG allows confounders, mediators and colliders to be distinguished when planning multivariable analyses. 16 A DAG was constructed to represent plausible causal assumptions about the relationship between lifetime history of mania/BD and cognitive performance, in the context of possible 8 confounding factors and intermediate pathways. This was done before any data were analysed. The nodes in the DAG and the assumed directional relationships between them were determined from previous systematic reviews of cognitive function in BD, 3, 5, [17] [18] [19] [20] [21] [22] [23] [24] as well as general background knowledge and assumptions regarding other shared causes that were necessary to depict in order for the DAG to have a causal interpretation. 16 The fit of the DAG to the data was then evaluated by estimating partial correlation coefficients for each pair of nodes that were predicted to be independent. Detection of a correlation between nodes that were predicted to be independent may indicate that the DAG has been misspecified. Where the results indicated lack of independence (i.e. partial correlation coefficient >|0.1| 25 ), followup regression models were conducted to obtain further detail. Modifications to the structure of the DAG were then considered. A detailed account of the construction and evaluation of the DAG is provided in the eMethods in the Supplement.
The DAG used in the major depression analyses was based on the final DAG used in the mania/BD analyses, with an arrow added from gender to major depression; studies have consistently shown higher prevalence of depression in women, 26 and it was assumed in the DAG that this relationship was at least partly causal. No arrows were removed compared with the mania/BD DAG, on the assumption that similar causal relationships might be operating to explain cognitive impairment in both disorders.
Total effects
The total effect of each mood disorder exposure on cognitive performance was firstly identified in the DAGs using DAGitty software. 27 The DAGitty algorithm applies 'dseparation' rules 8, 28 to find all the confounding paths between the exposure and the outcome, and ascertains if there is a set of nodes which, if conditioned on in the analysis, would 'block' these confounding paths. This information was then used to plan regression-and matching-based analyses to estimate the effect in the dataset. This was estimated separately for each of the five cognitive outcome measures, to allow for the possibility of task-specific variation in the results. Results are reported as standardized mean differences or risk differences with 95% confidence intervals (CI). Further details of the estimation methods are given in the eMethods in the Supplement.
Mediation analyses
The DAGs were used to assess whether indirect effects via various mediators of interest could be identified. This required all confounding paths between the exposure and the mediator and between the mediator and the outcome to be blocked, as well as those between the exposure and the outcome. Where this requirement was satisfied (i.e. covariate adjustment sets could be found), G-computation was used to estimate the natural direct and indirect effects. 29 This was implemented using the Stata package gformula; 30 gformula permits mediation analysis in the presence of intermediate confounding, whereby a mediatoroutcome confounder is itself caused by the exposure. Results are reported as standardized mean differences or risk differences with 95% CI.
Sensitivity analyses
Additional analyses were conducted to evaluate the sensitivity of the results to various potential sources of bias, including residual confounding, missing data, and exposure misclassification (see eMethods in the Supplement). These informed our interpretation with regard to key threats to the validity of the analytic framework.
Reporting follows STROBE guidelines. 31
Results
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Evaluation of the graphical model
The original DAG is shown and explained in the eMethods in the Supplement. The different predicted independencies implied by alternative plausible specifications of this DAG were tested (see eResults in the Supplement for details). eFig. 3 in the Supplement shows the best fitting DAG, which was used as the basis for the analysis models.
Total effects
Only the visuospatial memory test ( Fig. 1) and, more equivocally, the prospective memory test (eFig. 4 in the Supplement) indicated a detrimental effect of mania/BD that remained evident in the multivariable models. The effect sizes were small: the mania/BD group scored approximately 0.2 SD lower than the unexposed comparison group on the visuospatial memory test, and the proportion of the mania/BD group succeeding on the prospective memory task was lower by approximately 5 percentage points (approximately 82% in the mania/BD group versus 87% in the unexposed group). The visuospatial and prospective memory estimates showed little change between the unadjusted and adjusted/matched models, whereas the estimates for the other three cognitive measures generally attenuated towards the null (see eFigs. 5 to 7 in the Supplement). conditions. The extended adjustment set ('all common ancestors') also included age and family history of depression. This extended adjustment set was used as the predictor set for the propensity score model. Ethnicity was accounted for in all the multivariable analyses and in the propensity score estimation by restricting these to participants of white British genetic ancestry. The GPS scores were residualized as described in the eMethods, and were entered as deciles, based on the distribution in the full analysis sample.
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Mediation analyses
Structural analysis of the DAG indicated that direct and indirect effects could be decomposed for two potentially modifiable mediators: cardiometabolic disease and psychotropic medication. Further details of these models are provided in the eResults in the Supplement.
There was no evidence of substantive indirect effects via cardiometabolic disease in any of the models (eTable 8 in the Supplement).
There was evidence that the previously-noted detrimental effect of mania/BD on visuospatial memory was indirectly transmitted via psychotropic medication (eTable 9 in the Supplement). Of the estimated total effect of -0.19 SD units (95% CI -0.31 to -0.08), approximately one quarter was mediated via psychotropic medication (-0.05; 95% CI -0.09 to -0.01). Indirect effects were also evident in the reasoning, reaction time and prospective memory models, although the total effects estimates in these models did not show reliable decrements for mania/BD.
Sensitivity analyses
The results of the sensitivity analyses are provided in the eResults in the Supplement. Briefly, these indicated that: the total effects results for visuospatial memory are likely to be sensitive to exposure misclassification and would not be robust to an unmeasured confounder with even a weak association with exposure group membership (leading to minimally unbalanced odds of exposure, i.e. 45/55); the total effects results showed less attenuation when missing covariate data were imputed; the mediation results with missing covariate data imputation showed stronger evidence for an indirect effect via psychotropic medication but no evidence of an indirect effect via cardiometabolic disease; the DAGitty algorithm determined that there 15 were six other DAGs that were equivalent to the DAG shown in eFig. 3 in the Supplement, but none of these alternative configurations was causally plausible.
Cognitive Impairment in Major Depression
Characteristics of the sample eFig. 9 in the Supplement shows that the analysis sample comprised 50,975 participants with major depression and 102,931 comparison participants. 
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The different predicted independencies implied by alternative plausible specifications of the DAG were tested (see eResults in the Supplement). The best fitting DAG followed the same structure as that used in the mania/BD analysis, with the addition of a path between gender and major depression.
Total effects
Major depression was negatively associated with visuospatial memory performance in the multivariable models (Fig. 2) . The effect size was very small, with the major depression group scoring approximately 0.07 SD lower than the comparison group. Group differences were not seen on the other cognitive measures (eFigs. 10 to 13 in the Supplement). conditions. The extended adjustment set ('all common ancestors') also included age and family history of depression. This extended adjustment set was used as the predictor set for the propensity score model. Ethnicity was accounted for in all the multivariable analyses and in the propensity score estimation by restricting these to participants of white British genetic ancestry. The GPS scores were residualized as described in the eMethods, and were entered as deciles, based on the distribution in the full analysis sample.
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Mediation analyses
As with the mania/BD analyses, direct and indirect effects could be decomposed via cardiometabolic disease and via psychotropic medication (see eResults in the Supplement).
There was no evidence of substantive indirect effects via cardiometabolic disease in any of the models (eTable 16 in the Supplement). There was little evidence of mediation via psychotropic medication (eTable 17): approximately one third of the total effect on visuospatial memory (itself of very small magnitude, at -0.058) was estimated to be indirect, but the confidence interval included the null (-0.019; 95% CI -0.040 to 0.003).
Sensitivity analyses
The sensitivity analyses (eResults in the Supplement) indicated that: the total effects results for visuospatial memory are likely to be sensitive to exposure misclassification and would not be robust to an unmeasured confounder with even a very weak association with exposure group membership; the total effects results for reaction time showed less attenuation when missing covariate data were imputed; the mediation results with missing covariate data imputation showed stronger evidence for an indirect effect via psychotropic medication but no evidence of an indirect effect via cardiometabolic disease; there were six structurally equivalent DAGs but none were causally plausible.
Discussion
This study demonstrates small but robust associations between mood disorders and cognitive approximately one-quarter of the total effect, but (perhaps surprisingly) not through cardiometabolic disease. The total effect of major depression on cognitive performance followed a similar pattern to that of mania/BD, though with an effect size of around one-third the magnitude. The proportion of the total effect mediated by psychotropic medication was similar to that in mania/BD, but the confidence interval was wide and the estimate was reliably different from the null only after imputation of missing data. The effect estimates for both mood disorders are likely to be sensitive to residual confounding and exposure misclassification, and they may be biased toward the null as a result of missing covariate data.
The complexity inherent in this area was acknowledged and addressed by developing and evaluating comprehensive graphical models and by incorporating a broad range of genetic, sociodemographic, environmental, lifestyle and clinical measures in the analyses. Model estimation was conducted in multiple ways, and quantitative and graphical sensitivity analyses were carried out to investigate the robustness of the results to key assumptions. The sample sizes were substantially larger than those used in previous studies in the field, allowing small effect sizes to be estimated with precision.
The observed gradation in severity of impairment on the visuospatial memory task across mania/BD and major depression is congruent with previous reports, 7 although the magnitude of the difference compared with the non-mood-disorder group is notably smaller. [17] [18] [19] 22 The absence of group differences on the other cognitive tasks was surprising, in light of previous research showing multi-domain impairments, and it remains unclear to what extent this reflects insufficient adjustment for confounding in previous studies, the characteristics of the UK Biobank cohort, or the possibility that memory performance is a particularly sensitive marker of cognitive function in mood disorders.
The results also contribute to the evidence base on the relationship between psychotropic medication and cognitive impairment, which has been repeatedly highlighted in previous studies. 32 Mediation analyses, taking account of intermediate confounders such as past depressive episodes, indicated that an appreciable proportion of the detrimental effect of mania/BD on visuospatial memory performance was accounted for by this. The interplay between reasons for prescribing-especially of antipsychotic medications-and affective remission in understanding this relationship is not yet understood, but the present results appear to confirm that psychotropic medications warrant closer study as potential modifiable causes of cognitive impairment in mood disorders.
Limitations
The analyses were necessarily limited by the data collected in the UK Biobank resource:
many of the measures were brief, key cognitive functions such as verbal memory were not assessed, and clinician diagnoses were unavailable. The reliability of some of the cognitive measures is suboptimal. 14 This may cause imprecision in effect size estimates, 33 but such imprecision is mitigated by the large sample size in the present study. However, imprecision that is not due to random error could result in underestimated magnitudes of associations. The cognitive tests administered in UK Biobank may be less sensitive than the neuropsychological assessments used in clinical studies, which may partly account for the small group differences observed here. Assumptions about the temporal order of the variables could not be verified empirically. Conducting estimation one mediator at a time may lead to erroneous conclusions about the contribution of each mediator to the overall effect. 34 Possible collider stratification bias should be acknowledged; 35 it is likely that people with less severe 22 mood disorder history and better cognitive function will have joined UK Biobank, and this will have been amplified further in the patterns of missingness across the cognitive outcome measures and the covariates. What is unknown, however, is the magnitude of the bias arising from collider stratification, and how this compares with similar or opposing biases from residual confounding. The missing-at-random assumption that is required for multiple imputation is arguably not valid for some of the measures in these analyses, given the probability that, for example, missingness on mental health-related measures will be influenced by true mental health status. Finally, the UK Biobank cohort is not representative of the UK population; associations may be heterogeneous across other populations. 36 
Conclusions and Future Directions
A small group difference in visuospatial memory performance was observed between mood disorder and comparison groups in this large general population cohort. Mediation analyses highlighted a potential causal pathway through psychotropic medication use. Our understanding of causal pathways towards cognitive impairment in psychiatric and neurological conditions will improve as the UK Biobank cohort is followed up over time, and other prospective cohorts such as the Avon Longitudinal Study of Parents and Children 37 mature into adulthood. The availability of a fuller range of background and intermediate data,
including early life factors, premorbid cognitive ability measures and brain imaging, will expand the kinds of causal effects that can be identified in models such as those proposed here. Linkage with prescribing data will permit more detailed investigation of the role of different classes of psychotropic medication, and combinations thereof, in explaining adverse cognitive outcomes.
